Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classificação em ações #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Preço da ação
$8.74
Última sincronização: 2026-08-28
Valor de mercado
$699.74M
Variação (1 dia)
-4.85%
Variação (1 ano)
-2.29%
País
US
Negociar BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoria

EPS de BridgeBio Oncology Therapeutics Inc. (BBOT)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da BridgeBio Oncology Therapeutics Inc., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da BridgeBio Oncology Therapeutics Inc. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH